Icotrokinra (JNJ-2113)
Moderate-to-Severe Plaque Psoriasis
Key Facts
About Protagonist Therapeutics
Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.
View full company profileAbout Protagonist Therapeutics
Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.
View full company profileAbout Protagonist Therapeutics
Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.
View full company profileAbout Protagonist Therapeutics
Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| AC-201 | Accro Bioscience | Phase 2 |
| ICOTYDE (icotrokinra) | johnson-and-johnson-innovative-medicine | Approved |
| TAK-279 (NDI-034858) | Takeda | Phase 3 |
| ILUMYA® (tildrakizumab-asmn) | Sun Pharmaceutical | Commercial |
| Iruxolimab (AK101) | Akeso | Approved |
| Envudeucitinib (ESK-001) | Alumis | Phase 3 |
| ORKA-001 | Oruka Therapeutics | Phase 1/2 |